Neustar Expands European Data Scrubbing Estate to Build the World’s Largest DDoS Mitigation Defence Network
Neustar, Inc. (NYSE: NSR), a trusted, neutral provider of real-time information services, today announced the expansion of its DDoS mitigation defence network in EMEA. Scrubbing centres in London, Frankfurt, Amsterdam and Marseille have been expanded, while new facilities in Stockholm and Tokyo have gone live.
The new scrubbing centres were deployed in partnership with Arbor Networks to deliver the world’s largest, most distributed and technically advanced DDoS mitigation defence network.
Through to mid-2018, the Neustar Global DDoS Defence Network will continue to grow its scrubbing capacity, with scrubbing centres distributed across all regions. This will provide unequalled capacity, underpinned by the best mitigation technology available in market, and over 15 years of mitigation experience.
“As part of Neustar’s quest to end the DDoS attack arms race, the construction of our enhanced network with regionalised nodes is a game-changer for our customers”, said Barrett Lyon, General Manager, DDoS Defence, Neustar. “We are continually futureproofing the network to meet and defeat new attacks head-on, with enhanced and localised scrubbing. Put another way, unlike anything else available on the market today, Neustar is building a constantly evolving network that delivers clients with the required level of sophisticated DDoS defence capabilities needed to defend against the attacks of tomorrow,” Lyon added.
The Neustar Global DDoS Defence Network is integrated with the Neustar Web Application Firewall (WAF), protecting against sophisticated application layer attacks. The combination of technologies delivers multi-layered protection against the most aggressive and sophisticated attacks seen today.
The addition of the new nodes will mean a total network capacity exceeding any other DDoS mitigation network and achieve Neustar’s vision of providing a network that enables unrivalled mitigation capability and network performance, keeping its customers protected against any type of DDoS attack.
Neustar’s security solution, SiteProtect NG, breaks with the tradition of designing network protection that makes use of a high volume of small scrubbing centres with fewer, highly fortified and highly connected locations. SiteProtect NG network has deployed large, full scale, nodes, each with its multi-terabit scrubbing capacity in North America, Europe, and Asia with South America, Africa, Australia, and India slated for early 2018.
About Neustar Security Solutions
Neustar Security Solutions defend against network threats, inform you of potential network vulnerabilities, accelerate online asset performance, and monitor client website performance through multiple services and offerings. Neustar’s industry leading SiteProtect NG DDoS defense service ensures full layered coverage in an attack. Neustar UltraDNS service manages 10% of all internet traffic, routes over 1 trillion queries a month and provides industry leading uptime with 100% availability. Neustar IP Intelligence is the authoritative source of IP decisioning data on 99.99% of routable IP addresses worldwide. Our nearly 20 years of unparalleled expertise ensures that our customers are protected and optimized during normal business practices and when unsolicited events occur. Our services ensure customers network connectivity are protected and optimized whether in crisis or just business as usual. We are trusted by many of the world’s largest brands to keep their mission critical systems up and running. More information is available at www.security.neustar.
Neustar, Inc. is a leading global information services provider driving the connected world forward with trusted, holistic identity resolution. As the only company capable of understanding who is on the other end of every interaction, Neustar is trusted by the world’s great brands to grow and guard their businesses with the most complete knowledge of how to connect people, places and things. The combination of Neustar’s unique, accurate, and real-time identity system and our cloud-based workflow solutions empower our clients to make actionable, precise and valuable decisions across marketing, risk, IT/security, network & operations departments. As the sole provider of the U.S. Number Portability Administration Centre, Neustar also facilitates the routing of all telephone call and text messages in the U.S. More information is available at https://www.home.neustar.
Arbor Networks is a service mark of its owners and are used with permission.
Hotwire for Neustar
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 13:45 | Tiedote
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 12:10 | Tiedote
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30 | Tiedote
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 20:37 | Tiedote
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10 | Tiedote
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme